Replies to post #465935 on Anavex Life Sciences Corp (AVXL)

[rx7171]

Excellent comparison with MABs recently FDA approved.
Hard to imagine not get approved eventually.

[bb8675309]

Nice post, bas - A Comparison of the ADAS-Cog Scores for Aducanumab, Blarcamesine, Donanemab and Lecanemab!
2024 07/30 👏

Anavex Blarcamazine 2-73 is a superior drug.

Conclusions
Clearly, from this chart Blarcamesine has substantially better performance than the other drugs. The Blarcamesine trial had no inclusions or exclusions based on any tau or plaque or alleles. It is roughly 50% better than the "MABs".

Aducanumab, Donanemab and Lecanemab are monoclonal antibody drugs, frequently referred to as MABs. There were three different MAB drugs, independently developed by different companies, showing similar results. This data seems to raise the question, "Have the MABs reached their limit (approximately 27%) in slowing cognition decline?"

[powerwalker]

Thank you, Piotr Pietrzkiewicz, and to bas, too. Very telling! Good performance, blarcamesine and Anavex crew! 📣

[Rubyred77]

That’s only using the 48 week result for Blarcamesine correct?

Looking forward to what the OLE reveals